Parsortix Teams with Paterson Institute on Cancer Dx Tool | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The UK technology development firm Angle said today that Parsortix, a cancer diagnostics company in which it owns a 90 percent stake, will partner with the Paterson Institute for Cancer Research, based at the University of Manchester, UK, to develop circulating tumor cell-based technology for lung cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.